Maven Bio Claude Code plugin marketplace (Anthropic directory submission).
Install
npx skills add MavenBio/maven-bio-plugingh skill install MavenBio/maven-bio-plugingit clone --depth 1 https://github.com/MavenBio/maven-bio-pluginSkills in this collection
- Asset ProfileMaven BioBuild a full intelligence packet on one named drug or asset: development status, trial evidence, competitive position, catalysts, and risks. Use when someone names a single asset and wants depth, for example 'tell me everything about X', 'profile this drug', 'is X differentiated'. Use profile-entity instead when only a single structured fact sheet is wanted.
- Benchmark AssetsMaven BioCompare named assets side by side on a common set of dimensions and return a structured benchmark with explicit evidence strength. Use for direct comparisons, for example 'how does X compare to the other IL-23s', 'benchmark these four programs'. Use identify-analogs when precedents to reason from are wanted rather than a head-to-head table.
- Company PortfolioMaven BioBuild a full intelligence package on one company: pipeline, recent events, capital position, and strategic posture. Use when someone names a company and wants depth, for example 'profile Vertex', 'what is going on at X', 'walk me through their pipeline'. Use profile-entity instead when only a single structured fact sheet is wanted.
- Competitive PipelineMaven BioMap who is developing what for an indication, mechanism, or target, grouped by phase, company, or mechanism. Use for competitive questions, for example 'map the NSCLC landscape', 'who else is working on TL1A', 'what is the competition for X'. This is drug-program-centric: use indication-research when the question is about the disease itself, and funding-landscape when it is about capital flow.
- Deal ActivityMaven BioTrace BD deals (licensing, M&A, R&D collaborations, joint ventures) for a company, asset, indication, or deal type, and return structured deal-level evidence with provenance. Use for transaction questions, for example 'who has licensed X', 'what deals have been done in obesity'.
- Enumerate EntitiesMaven BioBuild the scoped list of drugs, companies, trials, mechanisms, or targets matching a set of criteria, without analyzing each one. Use when the job is to define the right set first, for example 'list every Phase 3 KRAS G12C program'. This is a building block: use competitive-pipeline when the landscape should be analyzed rather than listed.
- Financial ForecastMaven BioAssemble the assumptions behind a revenue or valuation forecast: population, penetration, pricing, timing, and competitive erosion, each with its evidence. Use when someone is building a model, for example 'what assumptions should I use for X', 'help me forecast peak sales'. Returns assumptions, not a finished spreadsheet or narrative. Use size-market when only sizing is wanted.
- Funding LandscapeMaven BioMap capital flow across a space: who is funding an indication, mechanism, target, or investor set, how much, and how it has moved over time. Use for market-level money questions, for example 'who is funding TL1A', 'how much has gone into obesity'. Use trace-financings when someone wants the round-by-round record for one company, and competitive-pipeline for drug programs rather than capital.
- Identify AnalogsMaven BioFind historical or competitive precedents that inform an asset, company, or market question, and explain why each is a fair comparison. Use for precedent reasoning, for example 'what is the closest analog to this launch', 'what should we price off'. Use benchmark-assets for a direct side-by-side comparison of named assets instead.
- Indication ResearchMaven BioBuild an evidence-backed picture of a disease: clinical context, epidemiology, unmet need, standard of care, and how the pipeline addresses it. Use for disease-first questions, for example 'tell me about ulcerative colitis', 'what is the unmet need in NASH'. Use competitive-pipeline when the question is really about competing drug programs, and size-market when only sizing is wanted.
- Profile EntityMaven BioReturn one structured, evidence-backed fact sheet for a single known drug, company, trial, mechanism, or target. This is a building block the workflow skills compose. Use it directly only when someone wants the raw fact pattern for one entity; for a full asset picture use asset-profile, and for a full company picture use company-portfolio.
- Size MarketMaven BioEstimate patient population and market size with explicit assumptions, evidence strength, and remaining uncertainty. Use when sizing is the question, for example 'how big is the market for X', 'how many patients are eligible'. Use financial-forecast when revenue projection assumptions are wanted, and indication-research for the broader disease picture.
- Synthesize EvidenceMaven BioTurn already-discovered facts into evidence-backed claims with evidence ratings, verbatim quotes, and canonical source references. Use as the final evidence pass before presenting findings, or when a claim must be tied back to a specific filing. This is a building block the workflow skills compose.
- Trace EventsMaven BioReturn the recent event stream (FDA actions, trial readouts, press releases) for a named drug, company, trial, or indication, with structured evidence per event. Use for recency questions, for example 'what happened with X recently', 'any news on this program'. This is a building block the workflow skills compose.
- Trace FinancingsMaven BioReturn the round-by-round financing record (amounts, dates, investors, provenance) for a named company, or filtered by indication, mechanism, target, or investor. Use when someone wants the actual rounds, for example 'list the funding rounds for X', 'who invested in their Series B'. Use funding-landscape when they want a market-level capital picture rather than a round list.
- Validate TargetMaven BioValidate the genetic basis of a drug target: gene-disease association strength, gene constraint, tractability, and known drugs, from public biomedical databases. Use when a thesis turns on whether a target is genetically validated.